Clinical prospects of long noncoding RNAs as novel biomarkers and therapeutic targets in prostate cancer

2015 ◽  
Vol 19 (1) ◽  
pp. 14-20 ◽  
Author(s):  
V Mouraviev ◽  
B Lee ◽  
V Patel ◽  
D Albala ◽  
T E B Johansen ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Noncoding Rnas ◽  
Therapeutic Targets ◽  
Long Noncoding Rnas ◽  
Novel Biomarkers

A preliminary analysis of LncRNA biomarkers for schizophrenia

Epigenomics ◽  
2021 ◽  
Author(s):  
Jiao Jia ◽  
Xiaofei Liu ◽  
Lina Ma ◽  
Yong Xu ◽  
Yan Ren
Keyword(s):  
Predictive Value ◽  
Preliminary Analysis ◽  
Noncoding Rnas ◽  
Therapeutic Targets ◽  
Long Noncoding Rnas ◽  
Antipsychotic Treatment ◽  
Treatment Results ◽  
Diagnosis And Prognosis ◽  
Before And After ◽  
Novel Biomarkers

Aim: The aim of this study was to identify the long noncoding RNAs (lncRNAs) associated with schizophrenia (SZ) and the relationships among their expression, antipsychotic efficacy and SZ severity. Method: The diagnostic and predictive value of nine lncRNAs, Gomafu, DISC2, PSZA11, AK096174, AK123097, DB340248, uc011dma.1, ENST00000509804-1 and ENST00000509804-2, was investigated in 48 patients with SZ before and after antipsychotic treatment. Results: Gomafu, AK096174, AK123097, DB340248, uc011dma.1, ENST00000509804-1 and ENST00000509804-2 were individually and collectively associated with, and predictive of, SZ pathogenesis. Moreover, increased expression of plasma AK123097, uc011dma.1 and ENST00000509804-1 levels was reversed after 12 weeks of antipsychotic treatment, which was associated with SZ severity. Conclusion: Seven lncRNAs serve as novel biomarkers for SZ diagnosis and prognosis and three lncRNAs are potential therapeutic targets.

Modulation of long noncoding RNAs by risk SNPs underlying genetic predispositions to prostate cancer

2016 ◽  
Vol 48 (10) ◽  
pp. 1142-1150 ◽  
Author(s):  
Haiyang Guo ◽  
Musaddeque Ahmed ◽  
Fan Zhang ◽  
Cindy Q Yao ◽  
SiDe Li ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Noncoding Rnas ◽  
Long Noncoding Rnas ◽  
Risk Snps

Long noncoding RNAs: New players in prostate cancer

2013 ◽  
Vol 339 (1) ◽  
pp. 8-14 ◽  
Author(s):  
Wen Cheng ◽  
Zhengyu Zhang ◽  
Jiangdong Wang
Keyword(s):  
Prostate Cancer ◽  
Noncoding Rnas ◽  
Long Noncoding Rnas

scholarly journals AR and ERG drive the expression of prostate cancer specific long noncoding RNAs

Oncogene ◽  
2020 ◽  
Vol 39 (30) ◽  
pp. 5241-5251
Author(s):  
Annika Kohvakka ◽  
Mina Sattari ◽  
Anastasia Shcherban ◽  
Matti Annala ◽  
Alfonso Urbanucci ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Noncoding Rnas ◽  
Long Noncoding Rnas

scholarly journals Long Noncoding RNAs Involved in the Endocrine Therapy Resistance of Breast Cancer

Cancers ◽  
2020 ◽  
Vol 12 (6) ◽  
pp. 1424 ◽  
Author(s):  
Toshihiko Takeiwa ◽  
Kazuhiro Ikeda ◽  
Yuichi Mitobe ◽  
Kuniko Horie-Inoue ◽  
Satoshi Inoue
Keyword(s):  
Breast Cancer ◽  
Endocrine Therapy ◽  
Noncoding Rnas ◽  
Therapeutic Targets ◽  
Therapy Resistance ◽  
Long Noncoding Rnas ◽  
Endocrine Therapy Resistance ◽  
New Biomarkers

Long noncoding RNAs (lncRNAs) are defined as RNAs longer than 200 nucleotides that do not encode proteins. Recent studies have demonstrated that numerous lncRNAs are expressed in humans and play key roles in the development of various types of cancers. Intriguingly, some lncRNAs have been demonstrated to be involved in endocrine therapy resistance for breast cancer through their own mechanisms, suggesting that lncRNAs could be promising new biomarkers and therapeutic targets of breast cancer. Here, we summarize the functions and mechanisms of lncRNAs related to the endocrine therapy resistance of breast cancer.

Sign in / Sign up

Export Citation Format

Share Document